Invesco’s Palvella Therapeutics PVLA Stock Holding History

Invesco’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.05M	Sell	48,527 -5,746	-11%	-$599K	﹤0.01%	2102
2025 Q4	$5.68M	Buy	54,273 +5,663	+12%	+$483K	﹤0.01%	2187
2025 Q3	$3.05M	Buy	+48,610	New	+$2.17M	﹤0.01%	2450
2021 Q4	–	Sell	-18,771	Closed	-$7.76M	–	4114
2021 Q3	$7.76M	Buy	+18,771	New	+$6.54M	﹤0.01%	2148
2021 Q2	–	Sell	-169	Closed	-$35K	–	4048
2021 Q1	$35K	Buy	169 +33	+24%	+$7.21K	﹤0.01%	3843
2020 Q4	$27K	Buy	+136	New	+$28.3K	﹤0.01%	3757
2019 Q4	–	Sell	-1,880	Closed	-$513K	–	3712
2019 Q3	$513K	Buy	+1,880	New	+$728K	﹤0.01%	3241
2019 Q1	–	Sell	-160	Closed	-$34K	–	3846
2018 Q4	$34K	Buy	160 +1	+0.6%	+$310	﹤0.01%	3731
2018 Q3	$71K	Sell	159 -333	-68%	-$145K	﹤0.01%	3804
2018 Q2	$199K	Sell	492 -996	-67%	-$474K	﹤0.01%	3706
2018 Q1	$812K	Buy	+1,488	New	+$921K	﹤0.01%	3120

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco's PVLA Position: Q1 2026 in Review

Invesco reduced its Palvella Therapeutics (PVLA) stake by 11% in Q1 2026, selling an estimated $599K and leaving 48,527 shares worth $6.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2102.

Invesco first reported a position in PVLA in Q1 2018 and has held it in 11 quarters since. The position peaked at $7.76M in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Invesco held 48,527 shares of Palvella Therapeutics worth $6.05M as of Q1 2026.
Invesco sold 5,746 Palvella Therapeutics shares in Q1 2026, an estimated $599K.
Palvella Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2102 holding.
Invesco first reported a position in Palvella Therapeutics in Q1 2018 and has held it in 11 quarters since.
Invesco's Palvella Therapeutics position peaked at $7.76M in Q3 2021.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.